title: Helodermin, helospectin, and PACAP stimulate cyclic AMP formation in intact bone, isolated osteoblasts, and osteoblastic cell lines.
abstract: Helodermin and helospectin are peptides structurally similar to vasoactive intestinal polypeptide (VIP) which were recently isolated from the salivary gland venom of the lizard Heloderma suspectum. Pituitary adenylate cyclase-activating polypeptide (PACAP) has been isolated from ovine hypothalamus and also shows sequence homology to VIP. A helodermin-like peptide has been detected by combined immunohistochemical and immunochemical techniques in the thyroid C-cells. In the present study, lizard helodermin was found to cause a time- and dose-dependent stimulation of cyclic AMP (cAMP) formation in neonatal mouse calvarial bones. Also, helospectin I, PACAP 27, and the C-terminally extended PACAP 38 stimulated cAMP accumulation in the mouse calvariae. The cAMP rise in response to helodermin was comparable to that induced by VIP, both in terms of potency and magnitude of the response. Helodermin, helospectin I, PACAP 27, and PACAP 38, at concentrations of 1 mumol/liter, stimulated cAMP accumulation in enzymatically isolated mouse calvarial bone cells. A significant response to all peptides was observed in both early and late released bone cells isolated from the calvariae, with low and high alkaline phosphatase activity, respectively. Helodermin and VIP stimulated cAMP accumulation in the cloned mouse calvarial osteoblastic cell line MC3T3-E1, in rat (UMR 106-01), and human (Saos-2) osteoblastic osteosarcoma cell lines, but not in the rat osteosarcoma cell line ROS 17/2.8. The effect of helodermin was synergistically and dose-dependently enhanced by forskolin (0.1 and 1 mumol/liter). These data show that bone cells, including osteoblasts, respond to several peptides of the VIP family, including helodermin, helospectin I, PACAP 27, and PACAP 38.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Oral Cell Biology, University of Umeå, Sweden.
authors.forename: U H
authors.initials: UH
authors.lastname: Lerner
authors.forename: P
authors.initials: P
authors.lastname: Lundberg
authors.forename: M
authors.initials: M
authors.lastname: Ransjö
authors.forename: P
authors.initials: P
authors.lastname: Persson
authors.forename: R
authors.initials: R
authors.lastname: Håkanson
mesh_terms: D016475:3T3 Cells; D000704:Analysis of Variance; D000818:Animals; D002460:Cell Line; D000242:Cyclic AMP / Q000378:metabolism*; D036341:Intercellular Signaling Peptides and Proteins; D008116:Lizards; D051379:Mice; D009479:Neuropeptides / Q000302:isolation & purification / Q000494:pharmacology*; D018377:Neurotransmitter Agents / Q000494:pharmacology; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D012516:Osteosarcoma; D010455:Peptides / Q000302:isolation & purification / Q000494:pharmacology*; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D051381:Rats; D014407:Tumor Cells, Cultured
chemical_list: C495402:Adcyap1 protein, mouse; C495403:Adcyap1 protein, rat; D036341:Intercellular Signaling Peptides and Proteins; D009479:Neuropeptides; D018377:Neurotransmitter Agents; D010455:Peptides; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; C040442:heliodermin; C043046:helospectin I; D000242:Cyclic AMP; D010741:Phospholipases A